Dosavadní zkušenosti s léčbou ropeginterferonem alfa-2b u pacientů s Ph negativními myeloproliferacemi na Interní hematologické a onkologické klinice LF MU a FN Brno
| Title in English | Current experience with ropeginterferon Alfa-2b in Ph negative myeloproliferative neoplasm at the Department of Internal Medicine – Haematology and Oncology in Brno |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Transfuze a Hematologie Dnes |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.prolekare.cz/casopisy/transfuze-hematologie-dnes/2022-4-18/dosavadni-zkusenosti-s-lecbou-ropeginterferonem-alfa-2b-u-pacientu-s-ph-negativnimi-myeloproliferacemi-na-interni-hematologicke-a-onkologicke-klinice-lf-mu-a-fn-brno-133047 |
| Doi | http://dx.doi.org/10.48095/cctahd2022prolekare.cz15 |
| Keywords | polycythemia vera; Ph negative myeloproliferative neoplasms; ropeginteferon alpha-2b |
| Attached files | |
| Description | Background: Ropeginterferon alfa-2b demonstrated efficacy and safety in patients with polycythaemia vera in the PROUD-PV and CONTINUATION-PV multicentric randomised studies. These studies reported the superior effect of ropeginterferon alfa-2b in attaining haematological and molecular remission during the fourth and fifth year of therapy. Patients and Methods: A total of 14 Ph-MPN patients treated with ropeginterferon alfa-2b at our Dept. of Internal Medicine – Haematology and Oncology were analysed from May 2020 to July 2022. Therapy duration, dosing, effect, and tolerance were evaluated. Results: Therapy median duration was 266 days. 14 patients in total were treated; 11 had polycythaemia vera (79%), 2 had essential thrombocythemia (14%), and one patient had secondary myelofibrosis post polycythaemia vera (7%). The median ropeginterferon alfa 2-b dose was 150 µg. Complete haematological remission was attained in 11 (79%) patients. Two patients (14%) had to discontinue treatment. During therapy, six patients (43%) suffered adverse events; only one patient (7%) developed a thromboembolic event. Conclusion: Our initial experience has confirmed the promising effect of ropeginterferon alfa 2-b on haematocrit control and its excellent tolerance among patients. |
| Related projects: |